Delta-Fly Pharma, Inc.
Notice Regarding Monthly Exercise Status of the 12th Series Stock Acquisition Rights Issued by Third-Party Allocation (with Exercise Price Adjustment Clause)
Monthly exercise status of stock acquisition rights disclosed. Exercises during the target month totaled 45,060 units (45.06% of the total issued 100,000 units), transferred treasury shares amounted to 5,020,000 shares, the number of listed shares at the time of payment was 14,305,000 shares, and exercise restriction is 31.50%.
Key Figures
- Delivered shares: 4,506,000 shares
- Number of stock acquisition rights exercised: 45,060 units
- Number of unexercised stock acquisition rights at month-end: 50,200 units
AI要約
Monthly Exercise Status and Current State of Stock Acquisition Rights
Delta-Fly Pharma, Inc. disclosed the monthly exercise status of the 12th series stock acquisition rights for September 2026. The delivered shares for the target month were 4,506,000 shares, and the number of stock acquisition rights exercised was 45,060 units (an exercise rate of 45.06% against the total issued 100,000 units). Unexercised rights at the end of the previous month were 95,260 units, and at month-end were 50,200 units; the exercise restriction is 31.50% against the total issued shares of 14,305,000 shares. Exercise dates were recorded over multiple days from September 1 to September 30.
Considerations on Share Issuance, Dilution, and Future Impact
The exercise of these stock acquisition rights has resulted in transferred treasury shares, and there are exemption conditions for the application of the exercise restriction. The notice also refers to special measures if monthly exercises exceed a certain proportion, so it is necessary to monitor the impact on future treasury share counts and the number of listed shares after the payment date. For detailed contractual terms, refer to the notice published on July 22.
Delta-Fly Pharma, Inc.
Company overview · Stock price · Financial data · All IR
